RANBAXY

Ranbaxy Laboratories Limited has informed the Exchange, vide letter dated September 17, 2013 regarding "Import Alert by USFDA".

Ranbaxy Laboratories Limited has informed the Exchange that: "In response to media reports pointing to USFDA website that Ranbaxy has received an Import Alert for its Mohali facility in India, we would like to inform you that the Company has so far not received any communication from the USFDA on this subject. We are seeking information from the USFDA in this regard."

Ranbaxy Laboratories Limited has informed the Exchange regarding press release dated September 05, 2013 titled "Ranbaxy Completes 20 Years in Russia".

Ranbaxy Laboratories Limited has informed the Exchange regarding the press release dated August 8, 2013 titled,"Ranbaxy allocated site for its Greenfield manufacturing facility in Malaysia-Agreement signed with Kulim Hi Tech Park."

Ranbaxy Laboratories Limited has informed the Exchange regarding Press Release dated August 7, 2013 titled "Ranbaxy Q2 CY 2013 Sales Rs.26,332 Mn. H1 CY2013 Sales Rs.50,730 Mn -Base business sales and margins grow"

Ranbaxy Laboratories Limited has submitted to the Exchange the Standalone and Consolidated Financial Results along with the Limited Review Report for the period ended June 30,2013.

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on July 10, 2013, allotted 28,520 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 423,129,509 Equity Shares of Rs. 5 each aggregating Rs. 2,115,647,545/-.

Ranbaxy Laboratories Limited has informed the Exchange regarding " Decision of European Commission".

Ranbaxy Laboratories Limited has submitted to the Exchange a copy of Press Statement dated May 31, 2013, which is being issued by the Company on May 31, 2013.

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated May 22, 2013, titled" Ranbaxy Highlights Improved Business and Quality Assurance Standards".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated May 13, 2013, titled" Ranbaxy announces conclusion of previously disclosed investigation by U.S. Department Of Justice".

Ranbaxy Laboratories Limited has informed the Exchange vide letter dated May 09, 2013 regarding the details of the Voting results at the Annual General Meeting of the Company held on May 07, 2013, under Clause 35A of the Listing Agreement.

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated May 08, 2013, titled "Ranbaxy Q1 CY 2013 Sales Rs.24,398 Mn. Base business grows by over 10%".

Ranbaxy Laboratories Limited has submitted to the Exchange the Standalone and Consolidated Financial Results along with the Limited Review Report for the period ended March 31,2013.

Ranbaxy Laboratories Limited has informed the Exchange regarding the Proceedings of the Annual General Meeting of the Company held on May 07, 2013.

Ranbaxy Laboratories Limited has informed the Exchange regarding a Press Release dated April 17, 2013 titled "Daiichi Sankyo and Ranbaxy launch hybrid business in Brazil to expand business of both companies".

Ranbaxy Laboratories Limited has informed the Exchange regarding a Press Release dated April 17, 2013, titled "Daiichi Sankyo and Ranbaxy launch hybrid business in Brazil to expand business of both companies".

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on April 15, 2013, allotted 94,136 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 423,100,989 Equity Shares of Rs. 5 each aggregating Rs. 2,115,504,945/-.

Ranbaxy Laboratories Limited has informed the Exchange regarding a Press Release dated April 01, 2013, titled "Ranbaxy resumes the supply of Atorvastatin tablets to the US market".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated March 05, 2013, titled "Ranbaxy to market Desvenlafaxine Base Extended Release Tablets in The US".

Ranbaxy Laboratories Limited has informed the Exchange that the Board of Directors at its meeting held on February 26, 2013 has decided to convene the Annual General Meeting (AGM) of the Company on May 07, 2013. Share transfer books for the purpose of AGM will remain closed from April 27, 2013 to May 07, 2013 (both days inclusive).

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated February 26, 2013, titled "Ranbaxy surpass 2012 guidance; Crosses Rs.120 Bn in Global sales".

Ranbaxy Laboratories Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended December 31,2012.

Ranbaxy Laboratories Limited has informed the Exchange regarding an update on Atorvastatin Recall, which is being issued by the Company on February 25, 2013.

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated January 16, 2013, titled "Daiichi Sankyo and Ranbaxy to leverage synergies in Thailand".

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on January 11, 2013, allotted 93,050 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 423,006,853 Equity Shares of Rs. 5 each aggregating Rs. 2,115,034,265/-.

Ranbaxy Laboratories Limited has informed the Exchange that the Allotment Committee of Directors through Resolution by Circulation passed on December 21, 2012, allotted 440,000 Equity Shares of Rs.5 each for cash at par to Ranbaxy ESOP Trust (Trust), set up to administer Ranbaxy Employee Stock Option Plan-2011. The Trust would allocate the shares to the employees of the Company and of its subsidiaries on exercise of stock options from time to time under Ranbaxy Employee Stock Option Plan - 2011. The paid-up Equity Share Capital of the Company post allotment is 422,913,803 Equity Shares of Rs.5

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated November 26, 2012, titled "Ranbaxy Launches Absorica (Isotretinoin) Capsules in the U.S. Healthcare Market".

Ranbaxy Laboratories Limited has informed the Exchange that the Company on November 23, 2012 has issued 5,000 Secured 9.20% Redeemable Non-Convertible Debentures of face value of Rs. 10,00,000/- each, for cash at par, aggregating Rs. 500 Crores, on a private placement basis, for general corporate purposes. These Debentures have been rated AA+ by CARE and are proposed to be listed on National Stock Exchange of India Ltd. (NSE).

Ranbaxy Laboratories Limited has informed the Exchange that the Company has made a recall of Atorvastatin from the USA market which will cause temporary disruption to that market of this product. The investigation with regard to the same of this issue is expected to be completed within two weeks and thereafter the Company expects to resume supplies.

Ranbaxy Laboratories Limited has submitted to the Exchange the Standalone and Consolidated Financial Results along with the Limited Review Report for the period ended September 30,2012.

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated November 08, 2012, titled "Ranbaxy delivers strong overall business performance; Improvement in base business sales and margins".

Ranbaxy Laboratories Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2012 as follows: Net Sales of Rs. 142803.8 lacs for the quarter ending on 30-SEP-2012 against Rs. 147275 lacs and Rs. 134916.2 lacs for the quarters ending on 30-JUN-2012 and 30-SEP-2011 respectively. Net Profit / (Loss) of Rs. 55219.2 lacs for the quarter ending on 30-SEP-2012 against Rs. (92566.6) lacs and Rs. (43919.6) lacs for the quarters ending on 30-JUN-2012 and 30-SEP-2011 respectively.

Ranbaxy Laboratories Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 30-SEP-2012 as follows: Net Sales of Rs. 265139.1 lacs for the quarter ending on 30-SEP-2012 against Rs. 317406 lacs and Rs. 202275.8 lacs for the quarters ending on 30-JUN-2012 and 30-SEP-2011 respectively. Net Profit / (Loss) of Rs. 75417.3 lacs for the quarter ending on 30-SEP-2012 against Rs. (58572.5) lacs and Rs. (46458) lacs for the quarters ending on 30-JUN-2012 and 30-SEP-2011 respectively.

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on October 11, 2012, allotted 208,854 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 422,473,803 Equity Shares of Rs. 5 each aggregating Rs. 2,112,369,015/-.

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated October 09, 2012, titled "RANBAXY LAUNCHES AUTHORIZED GENERIC OF EVOXAC IN THE U.S. HEALTHCARE MARKET".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated September 13, 2012, titled "RANBAXY GETS APPROVAL TO SET UP GREENFIELD MANUFACTURING FACILITY IN MALAYSIA".

Ranbaxy Laboratories Limited has informed the Exchange vide letter dated August 22, 2012 regarding "Development relating to withdrawal by Ranbaxy of 27 approved ANDAs in the USA market appearing on US Regulator website and on certain online portals".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated August 17, 2012, titled "Ranbaxy launches authorized Generic of Pioglitazone in the U.S.".

Ranbaxy Laboratories Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2012 as follows: Net Sales of Rs. 147275 lacs for quarter ending on 30-JUN-2012 against Rs. 124178.3 lacs for the quarter ending on 30-JUN-2011. Net Profit / (Loss) of Rs. (92566.6) lacs for the quarter ending on 30-JUN-2012 against Rs. 15037.5 lacs for the quarter ending on 30-JUN-2011.

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated August 09, 2012, titled "Ranbaxy returns sales growth of 55% in Q2 2012 with stronger profitability; receives approval for multiple value added, differentiated products".

Ranbaxy Laboratories Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 30-JUN-2012 as follows: Net Sales of Rs. 317406 lacs for quarter ending on 30-JUN-2012 against Rs. 205449.2 lacs for the quarter ending on 30-JUN-2011. Net Profit / (Loss) of Rs. (58572.5) lacs for the quarter ending on 30-JUN-2012 against Rs. 24323.5 lacs for the quarter ending on 30-JUN-2011.

Ranbaxy Laboratories Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended June 30,2012.

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated August 03, 2012 titled "RANBAXY ENTERS INTO AN IN-LICENSING AGREEMENT WITH GILEAD SCIENCES TO PROMOTE ACCESS TO REDUCED COST GENERIC EMTRICITABINE AND EMTRICITABINE-CONTAINING FIXED-DOSE ANTIRETROVIRALS IN DEVELOPING COUNTRIES".

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on July 11, 2012, allotted 152,361 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 422,264,949 Equity Shares of Rs. 5 each aggregating Rs. 2,111,324,745/-.

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated June 20, 2012 titled "Daiichi Sankyo and Ranbaxy Launch Hybrid Business in Venezuela".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated May 28, 2012, titled "Ranbaxy Announces USFDA Approval of CIP-ISOTRETINOIN NDA".

Ranbaxy Laboratories Limited has informed the Exchange vide notes to Accounts in the unaudited Financial Results for the quarter ended March 31, 2012 (taken on record by the Board of Directors of the Company at its meeting held on May 09, 2012) regarding Auditors Observations.

Ranbaxy Laboratories Limited has informed the Exchange that the voting results at the Annual General Meeting (AGM) of the Company held on May 08, 2012, in the prescribed format, pursuant to clause 35A of the Listing Agreement.

Ranbaxy Laboratories Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 09, 2012, have approved the appointment of Dr. Kazunori Hirokawa, as an Additional Director. Dr. Hirokawa, M. D. Ph.D, is a member of the Board, Senior Executive Officer and Head of Corporate Strategy Division of Daiichi Sankyo Company, Limited, Japan.